Влияние лечебно-профилактических препаратов на содержание триглицеридов в печени и сыворотке крови крыс, получавших высокожировой рацион на фоне дисбиоза и иммунодефицита

Abstract

При моделировании у крыс иммунодефицита (с помощью цитостатика циклофосфана) и дисбиоза (с помощью линкомицина) на фоне высокожирового рациона установлено повышение содержания триглицеридов (ТГ) в печени, а также содержания ТГ, холестерина и уровня печеночных маркеров (билирубин, АЛТ и щелочная фосфатаза) в сыворотке крови. Введение антидисбиотических препаратов (квертулин, квертгиал и лизоцим) снижало содержание ТГ в печени, а также уровень ТГ,холестерина и печеночных маркеров в сыворотке крови.

При моделюванні у щурів імунодефіциту (за допомогою цитостатика циклофосфана) і дисбіоза (за допомогою лінкоміцина) на тлі високожирового раціону встановлено підвищення вмісту тригліцеридів (ТГ) в печінці, а також вмісту ТГ, холестерину і рівня печінкових маркерів (білірубін, АЛТ і лужна фосфатаза) в сироватці крові. Введення антидисбіотичних препаратів (квертулін, квертгіал і лізоцим) знижувало вміст ТГ в печінці, а також рівень ТГ, холестерину і печінкових маркерів в сироватці крові.

In recent years there appeared data about close pathogenic connection of obesity with dysbiotic changes in organism. As is well known, the development of dysbiosis a large extent due to the presence in the body of immunodeficiency. The aim of our study was to investigate the effect on triglyceride content in the liver and in the blood serum of a number of new therapeutic and prophylactic agents with anti dysbiotic action. Such agents including kvertulin,lysozyme in gelatin and kvertgial. In work were used the following materials: quercetin; inulin made of chicory roots, calcium citrate; hyaluronic acid; lysozyme, of which was prepared the following drugs: In work were used the following materials: quercetin; inulin made of chicory roots, calcium citrate; hyaluronic acid; lysozyme, which was prepared from the following formulations: “Kvertulin”, “Kvertgial”, “Lysozyme in gelatin.” In experiments were used 35 Vistar line white rats. Dysbiosis was induced by antibiotic lincomycin. Immunodeficiency created by of cytostatic intraperitoneal injection cyclophosphamide. High fat diet (HFD) was prepared by adding 15 % of unrefined sunflower oil to the mixed fodder. Duration of experiment was 21 days. Therapeutic drugs started to to be entered from the first day of the experiment. Mortification of of animals was performed using thiopental anesthesia (20 mg / kg) at day 22 by total exsanguination from the heart. Prepared blood serum and liver part were excised, that was stored before the test at -30 °C. In liver homogenate was determined the contents of triglycerides (TG)and in blood serum except TG were determined cholesterol, bilirubin, ALT and alkaline phosphatase (ALP). In pathological liver significantly were increased fat content, which is significantly reduced under the influence of anti disbiotical drugs we tested, but the greatest degree (up to norm) — under the influence of Kvertulina. In the blood serum of rats with triple pathology significantly increase the content TG and cholesterol. Under the influence of anti disbiotic drugs TG content decreases slightly, whereas cholesterol was significantly reduced to near normal. Determination of hepatic markers in blood serum (bilirubin, ALT and alkaline phosphatase) showed a significant increase their level, indicating the development of hepatitis (steatohepatitis). Under the influence of anti disbiotic drugs, such as lysozyme and kvertulin was significantly reduced bilirubin level and ALT (almost back to normal), and alkaline phosphatase activity only tends to decrease. HFD on the background of dysbiosis and immunodeficiency causes the development of gepatosteatos and steatohepatitis, which is accompanied by hypertriglyceridemia and hypercholesterolemia. Anti disbiotic drugs, especially kvertulin containing hepatic protector quercetin, prebiotic inulin and calcium citrate has a pronounced therapeutic and preventive action, not only eliminating the hepatic steatosis, but also eliminating steatohepatitis.